Paul Vulto is CEO and co-founder of MIMETAS. Under his guidance, MIMETAS developed into a multinational company with operations in Europe, US and Japan. MIMETAS currently works with the majority of top-50 pharma companies and counts over 85 co-workers. Paul is the inventor behind the OrganoPlate® platform and PhaseGuide technology of MIMETAS. Prior to founding MIMETAS, Paul worked for the high-tech company Silicon Biosystems in Bologna, the Institute for Microsystems Engineering (IMTEK) at the University of Freiburg and the Leiden Academic Centre for Drug Research, Leiden University. Paul holds a cum Laude masters degree in Electrical Engineering and a cum Laude PhD degree in Microsystems Engineering.
Organ-on-a-Chip Technology as a Routine Tool in Drug Discovery and Development
Wednesday, 19 June 2019 at 09:30
Add to Calendar ▼2019-06-19 09:30:002019-06-19 10:30:00Europe/LondonOrgan-on-a-Chip Technology as a Routine Tool in Drug Discovery and DevelopmentOrgan-on-a-Chip and Tissue-on-a-Chip Europe 2019 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
Organ-on-a-Chip technology is a new paradigm in drug testing. The technology has as its aim to raise the physiological relevance of traditional cell culture by combining this with microfluidic techniques. Organs-on-a-Chip are 3D tissues that capture the complexity of in vivo tissues including 3D morphology, extracellular matrix embedment, multiple cell types, vascular structure and perfusion flow.
In this presentation I will introduce culture and interrogation of complex 3D tissues, such as liver, kidney, gut and brain tissue. The tissues are grown on the OrganoPlate® platform, that allow culturing of over 40 tissues in parallel. The tissues are embedded in an extracellular matrix gel and comprise both stromal tissue, bloodvessel structures as well as epithelial barriers with clear apical and basal sides. The platform can be interrogated using automated imaging equipment as well as all standard equipment including fluorescence-based assays, immuno-histochemical staining, barrier integrity monitoring, transport studies, viability assays, qRT-PCR, ELISA’s and many others. Last but not least, operation of the platform is thus straightforward that an end-user who is not necessarily an expert in the field of microfluidics is able to perform the study. In this presentation I will show examples of Organ-on-a-Chip tissues for use in drug safety testing and disease modeling.
Add to Calendar ▼2019-06-18 00:00:002019-06-19 00:00:00Europe/LondonOrgan-on-a-Chip and Tissue-on-a-Chip Europe 2019Organ-on-a-Chip and Tissue-on-a-Chip Europe 2019 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2019-06-19 09:30:002019-06-19 10:30:00Europe/LondonOrgan-on-a-Chip Technology as a Routine Tool in Drug Discovery and DevelopmentOrgan-on-a-Chip and Tissue-on-a-Chip Europe 2019 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
